Translations:Clostridium butyricum/4/en: Difference between revisions

From Azupedia
Jump to navigation Jump to search
VisualWikitext
FuzzyBot (talk | contribs)
15,166 edits
Importing a new version from external source
 
(No difference)

Latest revision as of 20:42, 17 April 2024

Information about message (contribute)
This message has no documentation. If you know where or how this message is used, you can help other translators by adding documentation to this message.
Message definition (Clostridium butyricum)
==Therapeutic uses==
The first ''C. butyricum'' MIYAIRI strain was isolated by Dr. Chikaji Miyairi from feces in Japan in 1933. In 1963, CBM 588 was isolated from a soil sample in [[Nagano, Nagano|Nagano]], Japan. Preparations based on CBM 588 have a long history of safe use in human populations in Japan, where such products are variously classed as pharmaceutical drugs, "quasi drugs", and OTC (Over The Counter) probiotics. The safe therapeutic use of CBM 588 in humans populations is supported by various peer-reviewed publications and case studies, including reports of CBM 588 use in severely-ill, immunocompromised, and hospitalized patients, as well as in pregnant women.

Therapeutic uses

The first C. butyricum MIYAIRI strain was isolated by Dr. Chikaji Miyairi from feces in Japan in 1933. In 1963, CBM 588 was isolated from a soil sample in Nagano, Japan. Preparations based on CBM 588 have a long history of safe use in human populations in Japan, where such products are variously classed as pharmaceutical drugs, "quasi drugs", and OTC (Over The Counter) probiotics. The safe therapeutic use of CBM 588 in humans populations is supported by various peer-reviewed publications and case studies, including reports of CBM 588 use in severely-ill, immunocompromised, and hospitalized patients, as well as in pregnant women.

Retrieved from "https://wiki.tiffa.net/w/index.php?title=Translations:Clostridium_butyricum/4/en&oldid=140410"